login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
CUE BIOPHARMA INC (CUE) Stock News
NASDAQ:CUE - Nasdaq -
US22978P1066
-
Common Stock
- Currency: USD
0.8829
-0.02 (-2.44%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CUE Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Chartmill
- Mentions:
GTI
ACM
GAME
SRPT
...
Get insights into the top gainers and losers of Wednesday's after-hours session.
9 days ago - By: Benzinga
- Mentions:
SSY
SRPT
PDSB
ATHA
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
10 days ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
24 days ago - By: Cue Biopharma, Inc.
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
a month ago - By: Cue Biopharma, Inc.
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
2 months ago - By: Zacks Investment Research
- Mentions:
FENC
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
2 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
3 months ago - By: Zacks Investment Research
- Mentions:
MXCT
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
3 months ago - By: Cue Biopharma, Inc.
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
3 months ago - By: Zacks Investment Research
- Mentions:
IRD
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
3 months ago - By: Zacks Investment Research
- Mentions:
HRMY
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
3 months ago - By: Yahoo Finance
- Mentions:
MU
REGN
RGEN
NVDA
...
Jim Cramer on Micron (MU): “No Catalyst, But You’re Buying Near the Low End”
3 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
3 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Announces Proposed Public Offering
3 months ago - By: Cue Biopharma, Inc.
Cue Biopharma to Host Business Update Call and Webcast
3 months ago - By: Cue Biopharma, Inc.
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
4 months ago - By: Benzinga
What's Going On With Cue Biopharma Shares Tuesday?
4 months ago - By: Zacks Investment Research
- Mentions:
NRIX
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
4 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
4 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Announces Strategic Organizational Transition
8 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Announces Strategic Organizational Transition
9 months ago - By: Cue Biopharma, Inc.
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
9 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
9 months ago - By: Cue Biopharma, Inc.
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Please enable JavaScript to continue using this application.